TCGA-52-7809-01A-21R-2125-07
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.560
- G2M_CHECKPOINT+0.460
- MITOTIC_SPINDLE+0.350
- MYC_TARGETS_V1+0.310
- MYC_TARGETS_V2+0.310
- DNA_REPAIR+0.300
- PANCREAS_BETA_CELLS+0.140
- SPERMATOGENESIS+0.120
- HEDGEHOG_SIGNALING+0.090
- KRAS_SIGNALING_DN+0.080
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.550
- INFLAMMATORY_RESPONSE-0.540
- ALLOGRAFT_REJECTION-0.500
- COAGULATION-0.460
- INTERFERON_GAMMA_RESPONSE-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- COMPLEMENT-0.440
- TNFA_SIGNALING_VIA_NFKB-0.440
- XENOBIOTIC_METABOLISM-0.440
- INTERFERON_ALPHA_RESPONSE-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_FBJ5Q54N | Embryonal tumors | — | 0.958 |
| 2 | BS_3F5PR9GS | medulloblastoma | — | 0.952 |
| 3 | BS_7XQRH69M | medulloblastoma | — | 0.944 |
| 4 | BS_TYAYZ9ZW | medulloblastoma | — | 0.941 |
| 5 | C3N-03886 | — | cohortMD1 | 0.940 |
| 6 | TCGA-BT-A2LA-01A-11R-A18C-07 | — | — | 0.940 |
| 7 | BS_3NWQXPQV | medulloblastoma | — | 0.938 |
| 8 | BS_W9AT0MR7 | medulloblastoma | — | 0.937 |
| 9 | BS_9PB3XH5D | medulloblastoma | — | 0.937 |
| 10 | BS_3V3KE3VT | medulloblastoma | — | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |